Kojie Pharma-B (02171): CT0596 has received IND approval from the National Medical Products Administration for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).

Zhiyuan Finance APP News, Keji Pharmaceuticals-B (02171) announced that CT0596, a universal CAR-T cell product targeting BCMA, has received IND approval from the National Medical Products Administration for the treatment of relapsed/refractory multiple myeloma (R/R MM) patients. The results of the IIT research for CT0596 were presented as a poster at the 2026 European Hematology Association (EHA) annual meeting.